This observation supports a view that the structural differences between IFN-β1a and IFN-β1b may be a direct impact on their efficacy by modulating response of immune system which is also in accordance with data obtained after long term IFN-β treatment MS patients (Stępień et al. 2013; Tiberio et al. 2005; Zivadinov et al. 2007) and indirectly by modulating NO/cGMP/PKG pathway (Guthikonda et al. 1998). Here, IFNB1 is linked to myeloid sarcoma.